Excited to share an article on Akebia Therapeutics, a biopharmaceutical developing cutting-edge therapies for the treatment of patients with kidney diseases. The Food and Drug Administration. (FDA) accepted the filing of the company's New Drug Application (NDA) for its lead product candidate, Vadadustat and has set a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022.
The Company has multiple strategic collaborations and partnerships with companies such as Mitsubishi Tanabe Pharma Corporation, Vifor Pharma, Janssen, Panion & BF Biotech and Japan Tobacco and is looking at expanding its pipeline through research and development, in-licenses, strategic collaborations and acquisitions.
Great work by John P. Butler and the entire team at Akebia!
AKEBIA SCORES ANOTHER POTENTIAL WIN IN KIDNEY DISEASE!